Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentSelling, General & Administrative
Others
Ratios

Larimar Therapeutics (LRMR) Interest & Investment Income (2016 - 2020)

Larimar Therapeutics (LRMR) has disclosed Interest & Investment Income for 6 consecutive years, with $335000.0 as the latest value for Q4 2019.

  • For the quarter ending Q4 2019, Interest & Investment Income fell 50.37% year-over-year to $335000.0, compared with a TTM value of $2.0 million through Dec 2019, up 5.29%, and an annual FY2019 reading of $2.0 million, up 5.29% over the prior year.
  • Interest & Investment Income was $335000.0 for Q4 2019 at Larimar Therapeutics, down from $451000.0 in the prior quarter.
  • Across five years, Interest & Investment Income topped out at $675000.0 in Q4 2018 and bottomed at $39000.0 in Q1 2015.
  • Average Interest & Investment Income over 5 years is $310300.0, with a median of $251500.0 recorded in 2017.
  • The sharpest move saw Interest & Investment Income soared 14200.0% in 2015, then crashed 50.37% in 2019.
  • Year by year, Interest & Investment Income stood at $193000.0 in 2015, then grew by 19.17% to $230000.0 in 2016, then rose by 11.3% to $256000.0 in 2017, then surged by 163.67% to $675000.0 in 2018, then tumbled by 50.37% to $335000.0 in 2019.
  • Business Quant data shows Interest & Investment Income for LRMR at $335000.0 in Q4 2019, $451000.0 in Q3 2019, and $561000.0 in Q2 2019.